Skip to content
The Peptide Effect
Comparison

AOD-9604 vs Semaglutide

AOD-9604 and semaglutide take fundamentally different approaches to fat loss. AOD-9604 (Advanced Obesity Drug) is a modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis and inhibits lipogenesis without the metabolic side effects of full HGH. Semaglutide is an FDA-approved GLP-1 receptor agonist that suppresses appetite centrally and produces ~15% total body weight loss. While AOD-9604 is popular in anti-aging clinics and far cheaper, it has failed to demonstrate meaningful weight loss in human clinical trials, whereas semaglutide has the strongest clinical evidence base of any obesity medication ever developed.

Side-by-side comparison diagram of AOD-9604 and Semaglutide mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaAOD-9604Semaglutide
Primary mechanismHGH fragment — stimulates lipolysis and inhibits lipogenesis via fat-specific beta-3 adrenergic pathwayGLP-1 receptor agonist — central appetite suppression, delayed gastric emptying, insulin sensitization
Best forTargeted fat metabolism support, body recomposition protocols, patients who cannot tolerate GLP-1 side effectsSignificant weight loss (>10%), type 2 diabetes, cardiovascular risk reduction
Route of administrationSubcutaneous injection (typically abdominal area)Once-weekly subcutaneous injection or once-daily oral tablet
Typical dosage250–300 mcg daily, injected on empty stomach0.25 mg escalating to 2.4 mg weekly (Wegovy)
Average weight lossNot demonstrated in Phase 3 trials; 2.8 kg average loss in failed Phase 2b (not significant vs placebo)~15.3% body weight at 68 weeks (STEP 1)
Half-life~30 minutes (very short, requires daily dosing)~7 days (once-weekly dosing)
FDA statusNot FDA-approved for any indication; GRAS status in Australia for food use only; clinical trials discontinuedFDA-approved: Wegovy (obesity, 2021), Ozempic (T2D, 2017)
Clinical evidence strengthWeak — Phase 2b trial failed primary endpoint; most evidence is preclinical (animal models)Very strong — multiple Phase 3 trials (STEP program), cardiovascular outcomes (SELECT), 30,000+ trial participants
Side effectsMinimal reported — injection site reactions, mild headache; does not affect blood sugar or IGF-1 levelsNausea (44%), vomiting (24%), diarrhea (30%), constipation (24%)
Effect on muscle massClaimed to preserve lean mass (HGH fragment — no anabolic effects but no catabolic effects)~25–40% of weight loss is lean mass (a concern with all GLP-1 agonists)
Effect on appetiteNo appetite suppression — works on fat cells directlyStrong appetite suppression — reduces hunger and food reward signaling
Approximate monthly cost$50–$150/month (research peptide)$1,350–$1,430/month (brand) or $200–$500 (compounded)

When to Choose Each

Choose AOD-9604

Cost-conscious individuals seeking mild fat metabolism support, body recomposition protocols combined with exercise, patients who cannot tolerate GLP-1 side effects, or those wanting a low-risk peptide without appetite/blood sugar effects

Choose Semaglutide

Anyone needing clinically meaningful weight loss (>10% body weight), patients with type 2 diabetes, cardiovascular disease risk reduction, or anyone wanting an FDA-approved medication with robust clinical evidence

Verdict

Semaglutide is the objectively superior choice for meaningful weight loss, backed by massive clinical trials, FDA approval, and proven cardiovascular benefits. AOD-9604 is popular in anti-aging and biohacking circles due to its low cost, minimal side effects, and theoretical fat-targeted mechanism, but it failed its pivotal clinical trial and lacks robust human evidence for weight loss efficacy. AOD-9604 may have a niche role in body recomposition protocols for individuals seeking modest fat metabolism support without appetite suppression or GI side effects, but anyone expecting significant weight loss should choose semaglutide or another proven GLP-1 agonist.

References

  1. A double-blind placebo-controlled trial of the efficacy and safety of AOD9604 in obese subjects (2009) — PubMed
  2. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  3. The lipolytic actions of GH and IGF-I and the metabolic effects of the AOD9604 peptide (2001) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed

Frequently Asked Questions

Why is AOD-9604 popular if it failed clinical trials?
AOD-9604 remains popular for several reasons: it is very affordable ($50–150/month vs $1,300+ for semaglutide), has virtually no side effects, does not suppress appetite (appealing to those who want to maintain their eating habits), and is widely promoted by anti-aging clinics and peptide vendors. Some users report subjective fat loss improvements, though this may be attributable to concurrent diet and exercise changes. Its HGH-fragment mechanism is theoretically appealing even if clinical data is disappointing.
Can I stack AOD-9604 with semaglutide?
Some clinics offer this combination, theorizing that semaglutide provides appetite suppression and systemic weight loss while AOD-9604 enhances fat-specific lipolysis. However, there are no clinical studies validating this combination, and the incremental benefit of adding AOD-9604 to semaglutide is unproven. Given semaglutide's strong efficacy alone, the added cost and complexity of AOD-9604 may not be justified. Consult a physician before combining peptides.
Does AOD-9604 affect blood sugar or insulin like HGH does?
No — this is AOD-9604's key advantage over full human growth hormone. AOD-9604 is specifically the lipolytic (fat-burning) fragment of HGH (amino acids 177-191) without the domains responsible for IGF-1 elevation, insulin resistance, or diabetogenic effects. Studies confirm it does not affect blood glucose, insulin, or IGF-1 levels, making it safe for diabetic or pre-diabetic individuals from a metabolic standpoint.
What happened in the AOD-9604 clinical trials?
Metabolic Pharmaceuticals conducted a Phase 2b trial in 2007 testing AOD-9604 orally in 536 obese patients over 24 weeks. The trial failed its primary endpoint — weight loss was not statistically significant compared to placebo (approximately 2.8 kg vs 1.5 kg). The company subsequently abandoned development. No further large-scale human trials have been conducted. The drug received GRAS (Generally Recognized as Safe) status in Australia for use as a food ingredient, but this is not equivalent to therapeutic approval.
Can AOD-9604 or semaglutide be used for spot fat reduction?
Neither compound produces true spot fat reduction in the way that term is commonly understood. Semaglutide causes systemic weight loss primarily through central appetite suppression, and fat loss occurs across the body. Some clinics inject AOD-9604 subcutaneously near targeted fat deposits and claim localized lipolytic effects, but there is no rigorous clinical evidence supporting site-specific fat loss from AOD-9604 injections. Studies suggest that fat loss from both compounds follows general patterns determined by genetics and hormonal factors. Consulting a healthcare provider about evidence-based body composition strategies is recommended.

Explore next